Antiarrhythmic peptides
Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.
1. A compound having the formula:
or a retro form, an all D form, or a retro all D form thereof, said compound optionally being cyclic through a covalent bond between N* and C*;
wherein:
X is H, Ac, TFa, DBF, ASAL optionally iodinated, or HP;
l and n are 1;
p and q are independently 0 or 1;
R c is the side chain of Gly;
R d is the side chain of Ala;
R f is the acid side chain of Gly;
R g is the side chain of L-Hyp, D-Hyp, Pro, D-Pro, Ncg, A2C, Gly, Asn, T4c, or Pc, if the compound is a cyclic compound, or R g is the side chain of D-Hyp, Pro, D-Pro, Ncg, A2C, Gly, Asn, T4c, or Pc, if the compound is a linear peptide, wherein said side chain of L-Hyp, D-Hyp, Pro, D-Pro, or Thio-Pro is cyclized by attachment to the N atom bonded to the C atom to which R g is attached;
R h is the side chain of Pro, D-Pro, or Ala, wherein said side chain of Pro or D-Pro is cyclized by attachment to the N atom bonded to the C atom to which R h is attached;
R i is the side chain of Tyr or D-Tyr, wherein the aromatic ring of said side chain is optionally substituted with one or more halogen groups;
R j is the side chain of Gln or Asn;
R 7 is OH or NH 2 , or is absent if the compound is cyclized between N* and C*, or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 7 is NH 2 .
3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R g is the amino acid side chain of Asn, D-4Hyp, or L-/D-Pro when said compound is a linear peptide, wherein, when R g is the amino acid side chain of D-4Hyp or L-/D-Pro, the side chain is cyclized by attachment to the N atom bonded to the C atom to which R g is attached.
4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R h is the amino acid side chain of Pro or D-Pro, wherein the side chain is cyclized by attachment to the N atom bonded to the C atom to which R h is attached.
5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R i is the amino acid side chain of Tyr.
6. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R j is the amino acid side chain of Asn.
7. The compound of claim 1 , wherein said compound is cyclo(-Gly-Ala-Gly-Hyp-Pro-Tyr-Asn-) (SEQ ID NO:287), or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein said compound is cyclo(-Tyr-Pro-4Hyp-Gly-Ala-Gly-Asn-) (SEQ ID NO: 174), or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Asn-) (SEQ ID NO:288), or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 , wherein said compound is cyclo(-Gly-Ala-Gly-Pro-Pro-Tyr-Gln-) (SEQ ID NO: 300), or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 , wherein said compound is Gly-Ala-Gly-Pro-Pro-Tyr-NH 2 (SEQ ID NO: 301), or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 , wherein said compound is Ac-D-Tyr-D-Pro-D-Pro-Gly-D-Ala-Gly-NH 2 , or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 , wherein said compound is Ac-D-Tyr-D-Hyp-D-Hyp-Gly-D-Ala-Gly-NH 2 , or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 , wherein said compound is Gly-Ala-Gly-Asn-Tyr-NH 2 (SEQ ID NO:254), or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is Ac or H and R g is selected from the group consisting of Pro, D-Pro, Hyp, D-Hyp, Gly, or Asn.